Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 2NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Squamous Cell Carcinoma of Head and Neck 114Head and Neck Neoplasms 98Thyroid Neoplasms 55Salivary Gland Neoplasms 55Oropharyngeal Neoplasms 35Mouth Neoplasms 33Tongue Neoplasms 30Thyroid Cancer, Papillary 26Laryngeal Neoplasms 26Adenocarcinoma, Follicular 23Nasopharyngeal Neoplasms 22Carcinoma, Non-Small-Cell Lung 22Breast Neoplasms 21Hypopharyngeal Neoplasms 20Uterine Cervical Neoplasms 19Colonic Neoplasms 19Carcinoma, Medullary 16Rectal Neoplasms 15Pancreatic Neoplasms 15Esthesioneuroblastoma, Olfactory 15Esophageal Neoplasms 15Anus Neoplasms 15Neoplasms 14Lung Neoplasms 14Thyroid Carcinoma, Anaplastic 13Stomach Neoplasms 13Melanoma 13Carcinoma, Renal Cell 12Urinary Bladder Neoplasms 11Prostatic Neoplasms 11

Interventions

Sorafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Familial medullary thyroid carcinoma × Head & Neck × Clear all
NCT00390325 2024-02-06

Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer

National Cancer Institute (NCI)

Phase 2 Completed
21 enrolled 15 charts
EndocrineHead & Neck

Familial medullary thyroid carcinoma, Carcinoma, Medullary, Multiple Endocrine Neoplasia Type 2a, Multiple Endocrine Neoplasia Type 2b

Data powered by HemOnc (CC BY 4.0) Colophon âš¡